Response and Resistance to RAS Inhibition in Cancer.
Cancer discovery
| Authors | |
| Abstract | RAS inhibitors have shown early evidence of efficacy in multiple cancer types, but clinical benefit is limited by acquired resistance. Development of best-in-class inhibitors, with optimal potency, selectivity, and pharmacokinetic properties, as well as effective and tolerable combination therapies will be needed to overcome resistance and maximize the clinical impact of RAS-targeted therapy. |
| Year of Publication | 2025
|
| Journal | Cancer discovery
|
| Pages | OF1-OF25
|
| Date Published | 04/2025
|
| ISSN | 2159-8290
|
| DOI | 10.1158/2159-8290.CD-25-0349
|
| PubMed ID | 40293709
|
| Links |